Metabolomic Evaluation of Neutrophilic Airway Inflammation in Cystic Fibrosis
- PMID: 25611918
- PMCID: PMC4524329
- DOI: 10.1378/chest.14-1800
Metabolomic Evaluation of Neutrophilic Airway Inflammation in Cystic Fibrosis
Abstract
Background: Metabolomic evaluation of cystic fibrosis (CF) airway secretions could identify metabolites and metabolic pathways involved in neutrophilic airway inflammation that could serve as biomarkers and therapeutic targets.
Methods: Mass spectrometry (MS)-based metabolomics was performed on a discovery set of BAL fluid samples from 25 children with CF, and targeted MS methods were used to identify and quantify metabolites related to neutrophilic inflammation. A biomarker panel of these metabolites was then compared with neutrophil counts and clinical markers in independent validation sets of lavage from children with CF and adults with COPD compared with control subjects.
Results: Of the 7,791 individual peaks detected by positive-mode MS metabolomics discovery profiling, 338 were associated with neutrophilic inflammation. Targeted MS determined that many of these peaks were generated by metabolites from pathways related to the metabolism of purines, polyamines, proteins, and nicotinamide. Analysis of the independent validation sets verified that, in subjects with CF or COPD, several metabolites, particularly those from purine metabolism and protein catabolism pathways, were strongly correlated with neutrophil counts and were related to clinical markers, including airway infection and lung function.
Conclusions: MS metabolomics identified multiple metabolic pathways associated with neutrophilic airway inflammation. These findings provide insight into disease pathophysiology and can serve as the basis for developing disease biomarkers and therapeutic interventions for airways diseases.
Figures




Similar articles
-
Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis.Eur Respir J. 2016 Dec;48(6):1612-1621. doi: 10.1183/13993003.00524-2016. Epub 2016 Nov 11. Eur Respir J. 2016. PMID: 27836957 Free PMC article.
-
Extracellular purines are biomarkers of neutrophilic airway inflammation.Eur Respir J. 2008 May;31(5):949-56. doi: 10.1183/09031936.00089807. Epub 2008 Feb 6. Eur Respir J. 2008. PMID: 18256064 Free PMC article.
-
Metabolomics analysis of bronchoalveolar lavage fluid predicts unique features of the lower airway in pediatric cystic fibrosis.J Cyst Fibros. 2024 Nov;23(6):1087-1094. doi: 10.1016/j.jcf.2024.04.017. Epub 2024 Jun 8. J Cyst Fibros. 2024. PMID: 38853065
-
The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis.Biomarkers. 2015 Feb;20(1):5-16. doi: 10.3109/1354750X.2014.983167. Epub 2014 Nov 18. Biomarkers. 2015. PMID: 25403491 Review.
-
Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications.Thorax. 2013 Dec;68(12):1157-62. doi: 10.1136/thoraxjnl-2013-203204. Epub 2013 May 23. Thorax. 2013. PMID: 23704228 Review.
Cited by
-
Agmatine accumulation by Pseudomonas aeruginosa clinical isolates confers antibiotic tolerance and dampens host inflammation.J Med Microbiol. 2019 Mar;68(3):446-455. doi: 10.1099/jmm.0.000928. Epub 2019 Jan 22. J Med Microbiol. 2019. PMID: 30688634 Free PMC article.
-
Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD.Chest. 2022 May;161(5):1239-1249. doi: 10.1016/j.chest.2021.10.049. Epub 2021 Nov 18. Chest. 2022. PMID: 34801592 Free PMC article.
-
The Effect of Chinese Herbal Medicine Formula mKG on Allergic Asthma by Regulating Lung and Plasma Metabolic Alternations.Int J Mol Sci. 2017 Mar 10;18(3):602. doi: 10.3390/ijms18030602. Int J Mol Sci. 2017. PMID: 28287417 Free PMC article.
-
Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity.Am J Respir Crit Care Med. 2018 Jan 1;197(1):79-93. doi: 10.1164/rccm.201701-0134OC. Am J Respir Crit Care Med. 2018. PMID: 28853905 Free PMC article.
-
Mucus Structure, Viscoelastic Properties, and Composition in Chronic Respiratory Diseases.Int J Mol Sci. 2024 Feb 5;25(3):1933. doi: 10.3390/ijms25031933. Int J Mol Sci. 2024. PMID: 38339210 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
- F32 HL008808/HL/NHLBI NIH HHS/United States
- P30 ES010126/ES/NIEHS NIH HHS/United States
- K23 HL089708/HL/NHLBI NIH HHS/United States
- P01 HL034322/HL/NHLBI NIH HHS/United States
- K23-HL089708/HL/NHLBI NIH HHS/United States
- P01 HL110873/HL/NHLBI NIH HHS/United States
- P50 HL107168/HL/NHLBI NIH HHS/United States
- HL107168/HL/NHLBI NIH HHS/United States
- HL34322/HL/NHLBI NIH HHS/United States
- P42-ES005948/ES/NIEHS NIH HHS/United States
- R01 HL116228/HL/NHLBI NIH HHS/United States
- P01-HL110873/HL/NHLBI NIH HHS/United States
- P30-ES010126/ES/NIEHS NIH HHS/United States
- P01-HL08808/HL/NHLBI NIH HHS/United States
- P01 HL108808/HL/NHLBI NIH HHS/United States
- P30-DK065988 (5-52184)/DK/NIDDK NIH HHS/United States
- P50-HL107168/HL/NHLBI NIH HHS/United States
- P30-ES10126/ES/NIEHS NIH HHS/United States
- P30 DK065988/DK/NIDDK NIH HHS/United States
- P42 ES005948/ES/NIEHS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical